Macquarie Group Ltd. lowered its holdings in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 22.2% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 70,000 shares of the biotechnology company’s stock after selling 20,000 shares during the period. Macquarie Group Ltd.’s holdings in Momenta Pharmaceuticals were worth $977,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of MNTA. Rhumbline Advisers raised its holdings in shares of Momenta Pharmaceuticals by 7.2% during the 3rd quarter. Rhumbline Advisers now owns 150,340 shares of the biotechnology company’s stock worth $2,781,000 after buying an additional 10,125 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Momenta Pharmaceuticals by 6.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 897,784 shares of the biotechnology company’s stock worth $16,609,000 after buying an additional 56,748 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Momenta Pharmaceuticals by 6.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 736,068 shares of the biotechnology company’s stock worth $13,617,000 after buying an additional 44,290 shares in the last quarter. American International Group Inc. raised its holdings in shares of Momenta Pharmaceuticals by 8.0% during the 3rd quarter. American International Group Inc. now owns 58,491 shares of the biotechnology company’s stock worth $1,082,000 after buying an additional 4,357 shares in the last quarter. Finally, Great West Life Assurance Co. Can raised its holdings in shares of Momenta Pharmaceuticals by 5.7% during the 3rd quarter. Great West Life Assurance Co. Can now owns 101,971 shares of the biotechnology company’s stock worth $1,937,000 after buying an additional 5,500 shares in the last quarter. 97.64% of the stock is owned by institutional investors.
In other Momenta Pharmaceuticals news, SVP Bruce Leicher sold 1,861 shares of the company’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $16.00, for a total value of $29,776.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Craig A. Wheeler sold 1,773 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $16.18, for a total value of $28,687.14. Following the completion of the sale, the chief executive officer now owns 258,713 shares in the company, valued at approximately $4,185,976.34. The disclosure for this sale can be found here. Insiders have sold a total of 70,836 shares of company stock worth $1,158,448 in the last 90 days. 4.40% of the stock is currently owned by corporate insiders.
MNTA has been the subject of a number of research analyst reports. Stifel Nicolaus raised Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the stock from $18.00 to $21.00 in a report on Thursday, February 22nd. BidaskClub upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, February 13th. ValuEngine upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, April 3rd. Finally, Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. Momenta Pharmaceuticals has an average rating of “Hold” and a consensus price target of $15.33.
Shares of MNTA stock opened at $17.50 on Friday. The firm has a market cap of $1,379.61, a P/E ratio of -14.58 and a beta of 1.64. Momenta Pharmaceuticals, Inc. has a twelve month low of $11.85 and a twelve month high of $19.25.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.18 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. The business had revenue of $64.60 million for the quarter, compared to analyst estimates of $66.59 million. Momenta Pharmaceuticals had a negative return on equity of 23.62% and a negative net margin of 63.43%. Momenta Pharmaceuticals’s quarterly revenue was up 88.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 EPS. analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.27 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Shares Sold by Macquarie Group Ltd.” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/momenta-pharmaceuticals-inc-mnta-shares-sold-by-macquarie-group-ltd.html.
Momenta Pharmaceuticals Profile
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.